Omnipaque 300 mg I/ml inj. opl. i.thec./i.arter./i.v. flac. Belgia - hollanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

omnipaque 300 mg i/ml inj. opl. i.thec./i.arter./i.v. flac.

ge healthcare bv-srl - johexol 647 mg/ml - oplossing voor injectie - 300 mg i/ml - johexol 647 mg/ml - iohexol

Omnipaque 350 mg I/ml inj. opl. i.thec./i.arter./i.v. flac. Belgia - hollanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

omnipaque 350 mg i/ml inj. opl. i.thec./i.arter./i.v. flac.

ge healthcare bv-srl - johexol 755 mg/ml - oplossing voor injectie - 350 mg i/ml - johexol 755 mg/ml - iohexol

Synacthen Depot 1 mg/ml inj. susp. i.m. amp. Belgia - hollanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

synacthen depot 1 mg/ml inj. susp. i.m. amp.

alfasigma s.p.a. - tetracosactideacetaat - eq. tetracosactide 1 mg/ml - suspensie voor injectie - 1 mg/ml - tetracosactideacetaat - tetracosactide

Kenacort-A 40, suspensie voor injectie 40 mg/ml Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

kenacort-a 40, suspensie voor injectie 40 mg/ml

triamcinolonacetonide 40 mg/ml - suspensie voor injectie - benzylalcohol (e 1519) 9,9 mg/ml ; carmellose natrium (e 466) ; natriumchloride ; natriumhydroxide (e 524) ; polysorbaat 80 (e 433) ; water voor injectie ; zoutzuur (e 507)

Triamcinolonacetonide Addimed suspensie voor injectie 40 mg/ml Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

triamcinolonacetonide addimed suspensie voor injectie 40 mg/ml

triamcinolonacetonide 40 mg/ml - suspensie voor injectie - benzylalcohol (e 1519) 9,9 mg/ml ; carmellose natrium (e 466) ; natriumchloride ; polysorbaat 80 (e 433) ; water voor injectie

Tivicay Euroopan unioni - hollanti - EMA (European Medicines Agency)

tivicay

viiv healthcare bv - dolutegravir - hiv-infecties - antivirale middelen voor systemisch gebruik - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Juluca Euroopan unioni - hollanti - EMA (European Medicines Agency)

juluca

viiv healthcare b.v. - dolutegravir natrium, rilpivirine-hydrochloride - hiv-infecties - antivirale middelen voor systemisch gebruik - juluca is geïndiceerd voor de behandeling van het humaan immunodeficiëntie virus type 1 (hiv-1) - infectie bij volwassenen die virologically-onderdrukt (hiv-1 rna.

Bimzelx Euroopan unioni - hollanti - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriasis - immunosuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Uplizna Euroopan unioni - hollanti - EMA (European Medicines Agency)

uplizna

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosuppressiva - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Advate Euroopan unioni - hollanti - EMA (European Medicines Agency)

advate

takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorragica - behandeling en profylaxe van bloedingen bij patiënten met hemofilie a (aangeboren factor-viii-tekort). advate bevat geen von willebrand factor in het farmacologisch effectieve hoeveelheden en is daarom niet vermeld in de von willebrand ziekte.